Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CASP1 | P29466 | 5/20 | 0.36 |
| ▸ | CASP7 | P55210 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.36 |
| ▸ | USP2 | O75604 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233029 | 0.90 | TDP1 (0.39) | CXCR3PTPN11 | |
| SCHEMBL3226945 | 0.89 | ALDH1A1 (0.36) | CXCR3PTPN11ALDH1A1CASP1CASP7 | |
| SCHEMBL3230746 | 0.85 | TRPV1 (0.39) | CXCR3 | |
| SCHEMBL3221968 | 0.83 | TRPA1 (0.37) | CXCR3ALDH1A1CYP1A2USP2HSD17B10 | |
| SCHEMBL3224078 | 0.82 | PTGS2 (0.35) | CXCR3 | |
| SCHEMBL3226615 | 0.81 | SCN9A (0.40) | PTPN11ALDH1A1CASP1CASP7CYP1A2 | |
| SCHEMBL3233019 | 0.79 | TDP1 (0.39) | — | |
| SCHEMBL3229356 | 0.78 | MEN1 (0.35) | CXCR3ALDH1A1CASP1CASP7CYP1A2 | |
| SCHEMBL5257112 | 0.78 | CXCR3 (0.34) | CXCR3ALDH1A1CASP1CASP7CYP1A2 | |
| SCHEMBL4299971 | 0.77 | PTGS2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
| US-7479558-B2 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | CXCR3 344/4885PTPN11 2591/4885ALDH1A1 865/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | CXCR3 479/4885PTPN11 3439/4885ALDH1A1 366/4885 |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | MAPKAPK2, CDC42BPB, MAP4K2 | CXCR3 949/4885PTPN11 1791/4885ALDH1A1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.